Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a ‘target trial’

• Published in: Open heart Vol. 9; no. 2; p. e001999
• Main Authors: Pufulete, Maria, Harris, Jessica, Pouwels, Koen, Reeves, Barney C, Lasserson, Daniel, Loke, Yoon K, Mumford, Andrew, Mahadevan, Kalaivani, Johnson, Thomas W
• Format: Journal Article
• Language: English
• Published: London British Cardiovascular Society 01.08.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: acute coronary syndrome; Acute coronary syndromes; Angioplasty; Aspirin; Body mass index; Cardiology; Cohort analysis; Diabetes; electronic health records; epidemiology; Heart attacks; Intervention; Interventional Cardiology; Kidney diseases; Mortality; Patients; percutaneous coronary intervention; pharmacology, clinical; Population-based studies; Stroke; United Kingdom > UK
• ISSN: 2053-3624; 2398-595X; 2053-3624
• DOI: 10.1136/openhrt-2022-001999

ObjectiveTo estimate the incidence and HRs for bleeding for different dual antiplatelet therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in England.DesignA retrospective, population-based cohort study emulating a target randomised controlled trial (tRCT).Data sourcesLinked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES).SettingPrimary and secondary care.ParticipantsPatients ≥18 years old with ACS undergoing emergency PCI.InterventionsAspirin and clopidogrel (AC, reference) versus aspirin and prasugrel (AP) or aspirin and ticagrelor (AT); AP evaluated only in patients with ST-elevation myocardial infarction (STEMI).Main outcome measuresPrimary: any bleeding up to 12 months after the index event (HES- or CPRD- recorded). Secondary: HES-recorded bleeding, CPRD-recorded bleeding, all-cause and cardiovascular mortality, mortality from bleeding, myocardial infarction, stroke, additional coronary intervention and major adverse cardiovascular and cerebrovascular events (MACCE).ResultsIn ACS, the rates of any bleeding for AC and AT were 89 per 1000 person years and 134 per 1000 person years, respectively. In STEMI, rates for AC, AP and AT were 93 per 1000 person years, 138 per 1000 person years and 143 per 100 person years, respectively. In ACS, compared with AC, AT increased the hazard of any bleeding (HR: 1.47, 95% CI 1.19 to 1.82) but did not reduce MACCE (HR: 1.06, 95% CI 0.89 to 1.27). In STEMI, compared with AC, AP and AT increased the hazard of any bleeding (HR: 1.77, 95% CI 1.21 to 2.59 and HR: 1.50, 95% CI 1.10 to 2.05, respectively) but did not reduce MACCE (HR: 1.10, 95% CI 0.80 to 1.51 and HR: 1.21, 95% CI 0.94 to 1.51, respectively). Non-adherence to the prescribed DAPT regimen was 28% in AC (29% in STEMI only), 31% in AP (STEMI only) and 33% in AT (32% in STEMI only).ConclusionsIn a real-world population with ACS, DAPT with ticagrelor or prasugrel are associated with increased bleeding compared with DAPT with clopidogrel.Trial registration numberISRCTN76607611.